價(jià)格 | ¥397 | ¥813 | ¥1230 |
包裝 | 1mg | 5mg | 10mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-29 |
中文名稱:奧潑佐米 | 英文名稱:Oprozomib |
CAS:935888-69-0 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.87% | 產(chǎn)品類別: 抑制劑 |
貨號(hào): T6041 |
名稱 | Oprozomib |
描述 | Oprozomib (PR-047) (ONX 0912) , an inhibitor for CT-L activity of 20S proteasome β5(IC50=36 nM)/LMP7(IC50=82 nM), is orally bioavailable. Oprozomib also has potential antineoplastic activity. |
細(xì)胞實(shí)驗(yàn) | MTT assay(Only for Reference) |
激酶實(shí)驗(yàn) | ELISA-based active site binding assay: Samples (lysed cells or tissue homogenates) are treated for 1 h at room temperature with the biotinylated active site probe PR-584 (5-15 μM). Samples are denatured by addition of SDS (0.9% final) and heating to 100 °C for 5 min. The denatured samples are transferred to a 96-well or 384-well filter plat, mixed with streptavidin-sepharose beads (2.5-5 μL packed beads/well), and incubated for 1 h at room temperature on a plate shaker. The beads are washed 5 times with 100-200 μL /well of ELISA buffer (PBS, 1% bovine serum albumin, 0.1% Tween-20) by vacuum filtration. The beads are incubated overnight at 4 °C on a plate shaker with the following antibodies recognizing the six catalytic subunits diluted into ELISA buffer: β5, β1, and β2 diluted 1:3000, LMP7 and LMP2 diluted 1:5000, and MECL-1 diluted 1:1000. The beads are washed 5 times with 100-200 μL /well of ELISA buffer and incubated with HRP-conjugated secondary antibody diluted 1:5000 in ELISA buffer and incubated 2 h at room temperature on a plate shaker. The beads are washed 5 times with 100-200 μL /well of ELISA buffer and developed for chemiluminsecence signal using the supersignal ELISA pico substrate following the manufacturer's instructions. Luminescence is measured on a plate reader and converted to ng of proteasome or μg/ml of lysate by comparison with 20S proteasome or untreated cell lysate standard curves. For proteasome inhibitor studies, active site probe binding values are expressed as the percent of binding relative to DMSO treated cells. |
體外活性 | 在多種人類腫瘤移植瘤和小鼠同系模型中,Oprozomib能夠抑制>80%蛋白酶,誘導(dǎo)抗腫瘤反應(yīng).Oprozomib經(jīng)過重復(fù)口服后,在動(dòng)物的大多數(shù)組織具有良好的安全性與耐受性. |
體內(nèi)活性 | Oprozomib具有抗MM活性,可以抑制MM細(xì)胞的遷移和血管生成。Oprozomib也能抑制caspase-8,caspase-9,caspase-3和PARP的激活。 |
存儲(chǔ)條件 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 93 mg/mL (174.6 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) |
關(guān)鍵字 | apoptosis | inhibit | bioavailable | immunoproteasome LMP7 | PR047 | PR 047 | Proteasome | Autophagy | orally | ONX0912 | ONX-0912 | Inhibitor | epoxyketone | Oprozomib |
相關(guān)產(chǎn)品 | Oxyresveratrol | Guanidine hydrochloride | Naringin | Taurine | Gefitinib | Hydroxychloroquine | Curcumin | Stavudine | Paeonol | Sodium 4-phenylbutyrate |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 自噬庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 抗代謝疾病化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊(cè)資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP13年
|
成都伊諾達(dá)博醫(yī)藥科技有限公司
|
2024-10-23 | |
詢價(jià) |
VIP7年
|
上海凡秦醫(yī)藥科技有限公司
|
2024-11-12 | |
¥1800 |
VIP9年
|
湖北威德利化學(xué)試劑有限公司
|
2024-11-15 | |
¥669.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 |